Abstract:
This research work investigated the influence of biofield treatment on Enterobacter cloacae (ATCC 13047) against antimicrobial susceptibility. Two sets of ATCC samples were taken in this experiment and denoted as A and B. ATCC A sample was revived and divided into two parts Gr. I (control) and Gr. II (revived); likewise, ATCC B was labeled as Gr. III (lyophilized). Group II and III were given with biofield treatment. The control and treatment groups of E. cloacae cells were tested with respect to antimicrobial susceptibility, biochemical reactions pattern and biotype number. The result showed significant decrease in the minimum inhibitory concentration (MIC) value of aztreonam and ceftazidime (≤ 8 μg/mL), as compared to control group (≥ 16 μg/mL). It was observed that 9% reaction was altered in the treated groups with respect to control out of the 33 biochemical reactions. Moreover, biotype number of this organism was substantially changed in group II (7731 7376) and group III (7710 3176) on day 10 as compared to control (7710 3376). The result suggested that biofield treatment had an impact on E. cloacae with respect to antimicrobial susceptibility, alteration of biochemical reactions pattern and biotype.
Enterobacter cloacae is a clinically significant Gram-negative, facultatively-anaerobic, rod-shaped bacterium.
In microbiology laboratories, E. cloacae is frequently grown at 30°C on nutrient agar or at 35°C in tryptic soy broth.[1] It is a rod-shaped, Gram-negative bacterium, is facultatively anaerobic, and bears peritrichous flagella. It is oxidase-negative and catalase-positive.[2]
Enterobacter cloacae has been used in a bioreactor-based method for the biodegradation of explosives and in the biological control of plant diseases.[3] Enterobacter cloacae strain MBB8 isolated from the Gulf of Mannar, India was reported to degrade poly vinyl alcohol (PVA). This was the first report of a PVA degrader from the Enterobacter genus. [4] E. cloacae was also reported to produce exopolysaccharide (EPS) as high as 18.3g/L. [5] GC-MS analysis of E. cloacae EPS showed the presence of glucose and mannose in the molar ratio of 1: 1.5e−2.[5]
Enterobacter cloacae subsp. cloacae strain PR-4 was isolated and identified by 16S rDNA gene sequence with phylogenetic tree view from explosive-laden soil by P. Ravikumar (GenBank accession number KP261383).[6]
E. cloacae SG208 identified as a predominant microorganism in mixed culture isolated from petrochemical sludge (IOCL, Guwahati) responsible for degradation of benzene was reported by Padhi and Gokhale (2016).[7]
Enterobacter cloacae is considered a biosafety level 1 organism in the United States and level 2 in Canada.
A draft genome sequence of Enterobacter cloacae subsp. cloacae was announced in 2012. The bacteria used in the study were isolated from giant panda feces.[8]
Enterobacter cloacae is a member of the normal gut flora of many humans and is not usually a primary pathogen.[9] Some strains have been associated with urinary tract and respiratory tract infections in immunocompromised individuals. Treatment with cefepime and gentamicin has been reported.[10]
A 2012 study in which Enterobacter cloacae was transplanted into previously germ-free mice resulted in increased obesity when compared with germ-free mice fed an identical diet, suggesting a link between obesity and the presence of Enterobacter gut flora.[11]
Enterobacter cloacae is a clinically significant Gram-negative, facultatively-anaerobic, rod-shaped bacterium.
